We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Idmos | IDO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.00 | 3.00 |
| Top Posts |
|---|
Posted at 22/2/2008 14:32 by nimh william (tryinghard2).. the only corporate update you'll get for IDO is that they'll be telling everyone that they are bust and shares will be suspended. |
Posted at 20/2/2008 16:26 by double6 Had a bit of a bad time lately, th ??ERX - big loss. PARO - big loss. IDO - big loss. We await the next one with scepticism! |
Posted at 08/2/2008 15:52 by tsmith2 IDMoS plc (the "Company")IDMoS plc (AIM: IDO) ("IDMoS" or the "Company"), the specialist in disease detection and monitoring technology, announces that further to the announcement made at 10.34 am this morning, 8th February 2008, the Company confirms a range of transactions are under contemplation with a private, profitable company including an offer for the entire share capital of the Company (IDMos). Discussions are at an early stage and accordingly no certainty can be forthcoming as to the terms on which any offer can be made. Do you think if you were the directors you'd wanna see £3m of your money P*ssed away - they will accept the bid one way or the other |
Posted at 08/2/2008 12:47 by double6 Additional RNS just released...."POSSIBLE OFFER IDMoS plc (AIM: IDO) ("IDMoS" or the "Company"), the specialist in disease detection and monitoring technology, announces that further to the announcement made at 10.34 am this morning, 8th February 2008, the Company confirms a range of transactions are under contemplation with a private, profitable company including an offer for the entire share capital of the Company. Discussions are at an early stage and accordingly no certainty can be forthcoming as to the terms on which any offer can be made." |
Posted at 08/11/2007 07:24 by jonwig More beastly behaviour?IDMoS plc (AIM: IDO), the specialists in disease detection and monitoring technology, today announces the retirement of Francis Madden, aged 69, from the Board of Directors, and from his position as Company Secretary with effect from 6th November 2007. Mr Madden has been on the Board since February 2003. The position of Company Secretary has been filled by the appointment of Malcolm Gillies, a Non-Executive Director of IDMoS plc and a solicitor. |
Posted at 30/5/2006 16:36 by trader2 John - thanks for reply. Still believe that there are far bigger issues to address - and that the prospect of these regulatory matters being show stoppers/slowers is small.Spent a while today trawling round Can't see any reference to IDO - product or up-coming technology. No trade show stuff - nothing. Light under bushels? |
Posted at 28/4/2006 05:19 by trader2 IC 28 April 2006IDMOS (IDO) IDMOS may be small, but its products target markets estimated by the company to be worth more than $8bn in annual sales. Its dental decay-detection product, CMS, is expected to be launched by the end of the year - assuming US and European approval is granted - and the market for this alone could be up to $4bn in sales a year. The company is also working on a product for head and neck cancer detection, a market that could be worth even more than that for the dental application. And chief executive Stephen Westwood says that other soft-tissue applications are in the pipeline, although these are confidential due to pending patent applications. Meanwhile, Mr Westwood says that IDMOS has enough cash to fund itself until CMS is commercialised, although the goal posts could move if approval is delayed. A three-dimensional version of the detector is expected to be launched in a year's time. The shares have slipped over the past few months. But Mr Westwood says that this is simply due to a lack of newsflow. So, with the launch of CMS due later this year, the shares rate good value. |
Posted at 25/4/2006 19:40 by jonwig Deafening silence from the market, but Citywire writes:Dental pioneer aims to banish fillings forever A revolutionary new device aimed at detecting early signs of teeth decay could be on the market by the end of the year, according to the AIM-listed company behind the project. IDMos, a 2001 technology spin out from the University of Dundee, has developed a system which enables a low level electric current to be passed across the teeth signalling decay and other problems at an early stage. Chief executive Stephen Westwood told Citywire: ' We are well down the road to obtaining regulatory approval in both the US and in Europe where we are targeting Germany France and Scandinavia. We hope to be ready for commercial launch by the end of the year.' He said: ' The advantage of adopting a preventative approach through our system is to improve oral healthcare and wherever possible avoid the need for fillings. ' The funding issues facing the UK dental market mean that the system is unlikely to be marketed in this country immediately. The likely cost of the unit somewhere between $12,000 and $15,000 (£6,700 8,400) could also push it beyond the reach of many UK dentists. IDMos (IDO) was reporting half-year losses, which widened from £725,000 to £1.1 million as development costs increased. But there are no immediate funding pressures, with £3 million cash still in the kitty. A new version of the system incorporating enhanced 3D images will be launched at a later stage. The shares were unchanged at 151p, valuing the business at £24 million. It floated at 135p last September. |
Posted at 24/4/2006 11:27 by jonwig Hi, Trader.I'm especially hoping for some indication of progress with the three year collaboration with ESKULAP (Poland - oncology apps) announced on 5 Sept last year. There are milestone payments (from IDO), so something might be said. Re my worries about them being over-confident, it may well be that, in fact, they will over-deliver: as yet we don't know. |
Posted at 05/9/2005 07:18 by jonwig This new agreement is further down the line, but very interesting:IDMoS plc (AIM: IDO), the specialist in disease detection and monitoring technology, is pleased to announce that its medical subsidiary, IDMoS Medical Limited, has entered into an agreement (the 'Agreement') with the partners of ESKULAP to progress the development of the application of its ACIST technology to detect and monitor cancerous tumours and related abnormal cell structures. IDMoS expects that the research and development programme for developing non invasive cancer detection and monitoring instruments will complete during 2008, ready for commercial launch by the end of that year. The Agreement sets out specific development milestones and timetables, upon the achievement of which, IDMoS will make stage payments totalling £100,000. I sensed, with the Interim Results, that they were keen to develop this aspect of their technology. A joint study with Polish academics is mentioned in the prospectus, and the Head of research at IDMoS is Professor Przemyslaw Los, Ph D, Reims, who latterly has been assistant and associate professor at the Department of Medicine and Dentistry at the Medical University of Wroclawin Poland. He retains this title on an honorary basis and provides an important link with the University and its research capabilities. Professor Los has particular expertise in electrical sensor technology, and has developed and patented sensors for the copper industry. After a period at the University of California in Berkeley working on diagnostic sensors, he became a visiting professor at the University of Dundee. [Copied from prospectus.] |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
